瑞信:維持京東健康(6618.HK)優於大市評級 目標價142港元
瑞信發表研究報吿指,京東健康(6618.HK)上半年收入按年升55.4%,大致符合預期;經調整純利為6.67億元人民幣,按年升80%,勝預期。該行維持其優於大市評級,目標價維持142港元。
瑞信指,公司與上游藥物及消費類健康護理品牌更深度的合作,例如上游公司與京東健康的強勁供應鏈及營運效率合作,結合上游公司的專業用藥指導與慢性病知識,可為用户提供更多具質素的選擇。
該行又指,京東健康的互聯網醫療服務能力正穩步提升,該公司有超過13萬位醫生及專家,以及開設24所專業醫務中心,以為用户提供專業及精確的服務,同時公司與線下醫療機構合作,提供“線上+線下”醫療服務,例如上半年啟用的河南的互聯網醫院。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.